Convergent Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Therapeutics · 200 employees
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual ta
Funding history
- Funding Round — $22.2M — Aug 2024
- Funding Round — $29.2M — May 2023
- Series series a — $90.0M — May 2023
Recent signals
- Jan 28, 2026: Convergent Therapeutics Appoints Elizabeth L. Montgomery as Chief People Officer
- Jan 06, 2026: Convergent Therapeutics and NorthStar Medical Radioisotopes Expand Partnership to Enhance Drug Product Manufacturing.
- Aug 13, 2024: Raised $22.2M
- Sep 06, 2023: Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
- May 22, 2023: Raised $29.2M
- May 03, 2023: Raised $90.0M in Series series a
See plans & pricing → Track Convergent Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.